-
Posted by
Two Blokes May 19, 2025 -
Filed in
Stock
-
4 views
ImmuPharma PLC (AIM:IMM) has said it is in active discussions with several global commercial partners following significant scientific breakthroughs in its flagship autoimmune programme, P140, as the drug discovery company released its full-year results. The London-listed group said recent discoveries had confirmed that P140 operates via a unique mechanism of action, was non-immunosuppressive, and had demonstrated both efficacy and safety in preclinical studies.
